Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/08/26	$9.730	-1.12%	9,355
28/08/26	$9.840	-2.67%	62,760
27/08/26	$10.11	+4.98%	47,598
26/08/26	$9.630	-1.03%	69,360
25/08/26	$9.730	+0.52%	31,391

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.840USD

Average target price

26.00USD

Spread / Average Target

+164.23%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX 18:37:17 31/08/2026 +04			5-day change	1st Jan Change
9.775 ^USD	-0.66%		+0.51%	+146.95%

08-20	Turn Therapeutics Announces Peer-Reviewed Research Showing Gx-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch	CI
08-18	Turn Therapeutics Inc. announced that it has received $1.35 million in funding	CI

Market Cap	293M 253M 237M 216M 407M 28.01B 409M 2.81B 1.1B 14.14B 1.1B 1.08B 46.89B	P/E 2026 *	-24.6x	P/E 2027 *	-25.2x
Enterprise Value	293M 253M 237M 216M 407M 28.01B 409M 2.81B 1.1B 14.14B 1.1B 1.08B 46.89B	EV / Sales 2026 *	586x	EV / Sales 2027 *	58.6x
Free-Float	45.25%	Yield 2026 *	-	Yield 2027 *	-

08-20	Turn Therapeutics Announces Peer-Reviewed Research Showing Gx-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch	CI
08-18	Turn Therapeutics Inc. announced that it has received $1.35 million in funding	CI
08-14	Turn Therapeutics Inc. announced that it expects to receive $1.35 million in funding	CI
08-13	Turn Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-20	Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target	MT
07-07	Turn Therapeutics Inc. Announces Final Stage 2 Design And Data-Driven Expansion Of GX-03 Phase 2 Program In Atopic Dermatitis	CI
07-07	Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis	MT
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell Microcap Growth Benchmark Index	CI
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell 3000E Growth Benchmark	CI
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell Microcap Index	CI
06-29	Turn Therapeutics Inc.(NasdaqGM:TTRX) added to Russell 3000E Index	CI
06-01	Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis	RE
06-01	Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis	CI

07-20	Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target	MT
22/10/25	Turn Therapeutics provides shareholder update highlighting continued execution across clinical and strategic milestones	RE

Turn Therapeutics Inc. Stock

Stocks

TTRX

US90021W1053

Biotechnology & Medical Research

Valuation : Turn Therapeutics Inc.

Chart: Turn Therapeutics Inc.

Latest news : Turn Therapeutics Inc.

Analysts' recommendations : Turn Therapeutics Inc.

Press Releases : Turn Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Turn Therapeutics Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08-20	Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch	BU
08-13	Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results	BU
07-28	Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026	BU
07-07	Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis	BU
07-07	Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis	BU

1 day	-0.66%
1 week	+0.51%
Current month	+16.38%
1 month	+16.38%
3 months	+53.71%
6 months	+183.66%
Current year	+146.95%

1 week	9.45	10.28
1 month	8.43	10.95
Current year	3.01	11.69
1 year	2.57	26.5
3 years	2.57	26.5
5 years	2.57	26.5
10 years	2.57	26.5

Manager	Title	Age	Since
Bradley Burnam CEO	Chief Executive Officer	48	06/01/2015
Zuraiz Chaudhary DFI	Director of Finance/CFO	31	01/05/2025
Conoon Kim CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Bradley Burnam CHM	Chairman	48	-
Neilesh Shailesh Ghodadra BRD	Director/Board Member	46	01/10/2018
Andrew Gengos BRD	Director/Board Member	61	01/01/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/05/26	Bradley Burnam	Don	Chief Executive Officer	-1,200,000	4.0285%
02/04/26	Bradley Burnam	Don	Chief Executive Officer	300,000	1.0188%
02/04/26	Arthur Golden	Don	Director	300,000	1.0188%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TURN THERAPEUTICS INC.	-0.66%	+0.51%	-	-	293M
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+91.62%	69.54B
ARGENX SE	-2.26%	+1.25%	+44.44%	+88.25%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	-3.57%	+0.49%	+35.74%	+10.62%	26.51B
INSMED INCORPORATED	+0.21%	-4.43%	-18.45%	+441.27%	25.89B
BIONTECH SE	-0.91%	-9.36%	+1.62%	-15.44%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+429.04%	20.22B
GENMAB A/S	-1.92%	+0.28%	+29.11%	-19.77%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.36%	-4.93%	+2.30%	+549.93%	15.69B
EXELIXIS, INC.	-0.93%	-1.12%	+45.08%	+140.91%	13.49B
Average	-1.59%	-1.33%	+52.81%	+190.72%	28.22B
Weighted average by Cap.	-1.74%	-1.50%	+49.62%	+149.76%

	2026 *	2027 *
Net sales	500K 431K 404K 369K 695K 47.79M 697K 4.79M 1.87M 24.12M 1.88M 1.84M 79.99M	5M 4.31M 4.04M 3.69M 6.95M 478M 6.97M 47.93M 18.7M 241M 18.77M 18.36M 800M
Net income	-11.95M -10.3M -9.65M -8.81M -16.6M -1.14B -16.65M -115M -44.68M -576M -44.86M -43.88M -1.91B	-12.32M -10.61M -9.95M -9.08M -17.11M -1.18B -17.17M -118M -46.06M -594M -46.24M -45.23M -1.97B
Net Debt	-	-